Clinical trialNCT04351555Active, not recruitingPhase 3Interventional

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

SponsorAstraZenecaEnrollment358Non-Small Cell Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jamie Chaft, MD
Memorial Sloan Kettering, USA
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Masahiro Tsuboi, MD
National Cancer Center Hospital East, Japan
Principal Investigator
clinicaltrials.gov ↗
Walter Weder, MD
Thoraxchirurgie Bethanien, Switzerland
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

158 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Austria

Research Site
Graz, Austria
Research Site
Vienna, Austria

Brazil

Research Site
Barretos, Brazil
Research Site
Fortaleza, Brazil
Research Site
Jaú, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Recife, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Santa Maria, Brazil
Research Site
São José do Rio Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil

Bulgaria

Research Site
Panagyurishte, Bulgaria
Research Site
Pleven, Bulgaria
Research Site
Sofia, Bulgaria

Canada

Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada

Chile

Research Site
Las Condes, Chile
Research Site
Santiago, Chile
Research Site
Santiago, Chile

China

Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Chongqing, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Hangzhou, China
Research Site
Kunming, China
Research Site
Nanchang, China
Research Site
Nantong, China
Research Site
Shandong, China
Research Site
Shanghai, China

118 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Cisplatin →Osimertinib →Pemetrexed →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Dec 2020
Primary completion: 15 Oct 2024
Completion: 13 Jun 2029
Last update posted: 5 Jun 2026
Registered enrollment: 358
Registry id: NCT04351555

Cross-registrations

EU-CTR / CTIS (EudraCT)2020-000058-89EU-CTR / CTIS (EudraCT)2022-502606-33-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.